NCT02764411View on ClinicalTrials.gov

Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations

PHASE3TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Capillary Malformations

Interventions

DRUG

Brimonidine 0.33% gel

Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks

Trial Locations (1)

M5G1X8

The Hospital For Sick Children, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Galderma R&D

INDUSTRY

lead

The Hospital for Sick Children

OTHER